Some patients, particularly those with long-standing diabetes, may develop impaired awareness of hypoglycaemia , where warning symptoms are diminished or absent, increasing the risk of severe episodes
Notably, only one registered clinical study exists to date, which evaluates an implant-based delivery system of Exenatide and is currently in Phase 1 with an Active, not recruiting status (NCT05670379), initiated on December 20, 2024, and expected to conclude by August 2025
FIGURE 1 2.1 The GLP-1 pathway influences different alcohol-mediated responses in animals 2.1.1 Alcohol consumption Using two different bottle choice models, alcohol drinking over a prolonged period of time can be monitored in animals ( Similar to the results obtained with acute injection, repeated liraglutide treatment (six injections over 2 weeks) of alcohol-experienced male rats has been shown to decrease both alcohol consumption and preference for alcohol ( Although the aforementioned preclinical studies with GLP-1R reveal a role for the receptor in alcohol drinking, the importance of GLP-1 itself has not been studied as intensely
Hence, in case of persistent albuminuria and/or uncontrolled metabolic risks (i.e., inadequate glycemic control, hypertension, overweight/obesity) on SGLT2i therapy, GLP-1RAs should be considered as the preferential add-on therapy in T2DM patients with chronic kidney disease